ScreenerHero

PBLSParabilis Medicines Inc. Common Stock

NAS · US · Healthcare · Biotechnology · parabilismed.com
39.36USD-4.74%Mkt Cap: 4.86B $P/E: —

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics thro…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.86B $
Enterprise Value3.82B $
Revenue (TTM)148.00K $
Gross Profit-12.95M $
Net Income (TTM)-145.89M $
Revenue/Share0.0150 USD
Last Price39.36 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees145
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-18.10
PEG—
EV/EBITDA-22.57
EV/Revenue25785.54
P/S33036.80
P/B4.67
EPS (TTM)-1.79
EPS (Forward)-2.19
52W Range
24.6688% of range41.35
52W High41.35 USD
52W Low24.66 USD
Profitability
Gross Margin0.00%
Oper. Margin-34382.43%
EBITDA Margin0.00%
Profit Margin0.00%
ROE882.89%
ROA-180.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-123.71M $
CapEx (TTM)306.00K $
FCF Margin—
FCF Yield—
Net Debt-1.07B $
Net Debt/EBITDA6.35
Balance Sheet
Debt/Equity-3.55
Current Ratio17.91
Quick Ratio17.83
Book Value/Sh8.482 USD
Cash/Share9.072 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)41.75 USD
Upside (mean)+6.1%
Target Range40.00 USD – 45.00 USD
$40.00+6.1% to mean$45.00
# Analysts4
Ownership
Shares Out.121.95M
Float82.07M
Insiders7.03%
Institutions81.77%
Short Interest
Short Ratio11.5d
Short % Float4.24%
Short % Out.4.18%
Shares Short5.12M
Short (prev mo.)2.77M
Technical
SMA 5031.48 (+25.0%)
SMA 20031.48 (+25.0%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)400.74K
Avg Vol (10d)344.50K
Technical Indicators
RSI (14)63.6
MACD2.2570
MACD Signal1.9311
MACD Hist.+0.3258
BB Upper41.32 USD
BB Middle35.82 USD
BB Lower30.31 USD
BB Width30.76%
ATR (14)2.501 USD
Vol Ratio (20d)1.01x